Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, Belfer Research Building, Room 530, 413 E. 69th Street, New York, NY, 10065, USA.
Department of Population Health Sciences, Weill Cornell Medicine, 402 E. 67th Street, New York, NY, 10065, USA.
Mol Med. 2021 Sep 16;27(1):112. doi: 10.1186/s10020-021-00366-4.
The ongoing global COVID-19 pandemic has thrown into sharp relief the gap between modern biology's ability to investigate and respond to a novel pathogen and modern medicine's ability to marshal effective front-line interventions to limit its immediate health impact. While we have witnessed the rapid development of innovative vaccines against SARS-CoV-2 using novel molecular platforms, these have yet to alter the pandemic's long-term trajectory in all but a handful of high-income countries. Health workers at the clinical front lines have little more in their clinical armamentarium than was available a century ago-chiefly oxygen and steroids-and yet advances in modern immunology and immunotherapeutics suggest an underuse of extant and effective, if unorthodox, therapies, which we now call "Extreme Immunotherapies for Pandemics (EIPs)."
持续的全球 COVID-19 大流行凸显了现代生物学调查和应对新型病原体的能力与现代医学调动有效一线干预措施以限制其直接健康影响的能力之间的差距。虽然我们已经看到使用新型分子平台快速开发针对 SARS-CoV-2 的创新疫苗，但除了少数几个高收入国家外，这些疫苗尚未改变大流行的长期轨迹。临床一线的卫生工作者在他们的临床武器库中几乎没有比一个世纪前更多的东西——主要是氧气和类固醇——然而，现代免疫学和免疫疗法的进步表明，现有的有效但非传统疗法（我们现在称之为“大流行极端免疫疗法”）的使用不足。
